newsfilter
← Latest News
GlobeNewswire·

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis (RA) in February